When a person suffers a stroke, physicians must restore blood flow to the brain as quickly as possible to save their life.
Those mixtures carried more drug, but they came with strong drawbacks that included pain at the injection site and added toxicity concerns. The ideal solution for patients and caregivers is a ...
Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, today announced that its Phase Ib/II study of ...
News-Medical.Net on MSN
Injectable nanomaterial reduces secondary brain injury after ischemic stroke
When a person suffers a stroke, physicians must restore blood flow to the brain as quickly as possible to save their life.
The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous (SC) formulation for the treatment of adult ...
CNW/ - Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Limited ("Sun Pharma"), is pleased ...
Fresenius Kabi, an Operating Company of Fresenius, and a leading provider of essential medicines and medical technologies, ...
Donald Trump has sparked a fresh round of health concerns after trying to conceal his hand bruising while meeting with ...
The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...
Hosted on MSN
Antibody injections could replace slow IV drips in treating many diseases, MIT scientists find
Patients who depend on antibody drugs often spend long hours in infusion centers. These medicines are vital for treating many cancers, autoimmune disorders and infectious diseases, but current ...
Lunsumio Velo is supplied as a ready-to-use, preservative-free solution in single-dose vials containing 5mg/0.5mL and 45mg/mL.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback